An FDA advisory committee on Wednesday unanimously voted against recommending approval of the PARP inhibitor talazoparib ...

Experts explain the science behind Biden's advanced prostate cancer diagnosis, including how common it is and what treatments are available.

In a somber end to an FDA advisory committee’s two-day scouring of multiple drugmakers’ oncology data, Pfizer’s pitch to ...

The objective of this study was to assess whether adding CAN-2409 in combination with the prodrug valacyclovir to standard of ...

Talzenna is currently approved in combination with Xtandi (enzalutamide) for individuals with castration-resistant prostate ...

The FDA’s ODAC has voted against the risk/benefit profile of two targeted therapies for the treatment of bladder and prostate ...

Ed Burgess, diagnosed with stage IV prostate cancer, shares his journey of survival thanks to a combination of hormone therapy and the drug enzalutamide, highlighting the personal impact of research ...

The FDA’s independent advisors found Pfizer’s data lacked the precision needed to establish the efficacy of Talzenna in ...

From my colleague Adam Feuerstein: French drug maker Sanofi is acquiring the small biotech Vigil Neuroscience for $470 ...

U.S. prices for new drugs more than doubled last year compared to 2021, as companies developed more therapies for rare ...

An eight-member panel voted unanimously against wider use of Pfizer’s Talzenna in advanced prostate cancer. Elsewhere, U.K.

The FDA’s On­co­log­ic Drugs Ad­vi­so­ry Com­mit­tee vot­ed 8-0 against a new in­di­ca­tion for Pfiz­er’s Talzen­na in com­bi­na­tion with Xtan­di for first-line treat­ment of adults with … Get free ...